Recent Advances in In Vivo Somatic Cell Gene Modification in Newborn Pups
-
Published:2023-10-18
Issue:20
Volume:24
Page:15301
-
ISSN:1422-0067
-
Container-title:International Journal of Molecular Sciences
-
language:en
-
Short-container-title:IJMS
Author:
Nakamura Shingo1ORCID, Morohoshi Kazunori1, Inada Emi2, Sato Yoko3, Watanabe Satoshi4, Saitoh Issei5ORCID, Sato Masahiro6ORCID
Affiliation:
1. Division of Biomedical Engineering, National Defense Medical College Research Institute, Tokorozawa 359-8513, Japan 2. Department of Pediatric Dentistry, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima 890-8544, Japan 3. Graduate School of Public Health, Shizuoka Graduate University of Public Health, Aoi-ku, Shizuoka 420-0881, Japan 4. Institute of Livestock and Grassland Science, NARO, Tsukuba 305-0901, Japan 5. Department of Pediatric Dentistry, Asahi University School of Dentistry, Mizuho 501-0296, Japan 6. Department of Genome Medicine, National Center for Child Health and Development, Setagaya-ku, Tokyo 157-8535, Japan
Abstract
Germline manipulation at the zygote stage using the CRISPR/Cas9 system has been extensively employed for creating genetically modified animals and maintaining established lines. However, this approach requires a long and laborious task. Recently, many researchers have attempted to overcome these limitations by generating somatic mutations in the adult stage through tail vein injection or local administration of CRISPR reagents, as a new strategy called “in vivo somatic cell genome editing”. This approach does not require manipulation of early embryos or strain maintenance, and it can test the results of genome editing in a short period. The newborn is an ideal stage to perform in vivo somatic cell genome editing because it is immune-privileged, easily accessible, and only a small amount of CRISPR reagents is required to achieve somatic cell genome editing throughout the entire body, owing to its small size. In this review, we summarize in vivo genome engineering strategies that have been successfully demonstrated in newborns. We also report successful in vivo genome editing through the neonatal introduction of genome editing reagents into various sites in newborns (as exemplified by intravenous injection via the facial vein), which will be helpful for creating models for genetic diseases or treating many genetic diseases.
Funder
Ministry of Education, Science, Sports, and Culture, Japan
Subject
Inorganic Chemistry,Organic Chemistry,Physical and Theoretical Chemistry,Computer Science Applications,Spectroscopy,Molecular Biology,General Medicine,Catalysis
Reference139 articles.
1. A most formidable arsenal: Genetic technologies for building a better mouse;Clark;Genes Dev.,2020 2. Sato, M., Takabayashi, S., Akasaka, E., and Nakamura, S. (2020). Recent Advances and Future Perspectives of In Vivo Targeted Delivery of Genome-Editing Reagents to Germ Cells, Embryos, and Fetuses in Mice. Cells, 9. 3. GONAD: Genome-editing via Oviductal Nucleic Acids Delivery system: A novel microinjection independent genome engineering method in mice;Takahashi;Sci. Rep.,2015 4. Ohtsuka, M., Sato, M., Miura, H., Takabayashi, S., Matsuyama, M., Koyano, T., Arifin, N., Nakamura, S., Wada, K., and Gurumurthy, C.B. (2018). i-GONAD: A robust method for in situ germline genome engineering using CRISPR nucleases. Genome Biol., 19. 5. National Academies of Sciences, Engineering, and Medicine, National Academy of Medicine, National Academy of Sciences, and Committee on Human Gene Editing: Scientific, Medical, and Ethical Considerations (2017). Human Genome Editing: Science, Ethics, and Governance, National Academies Press.
|
|